Drug companies are scrambling to try to convince FDA not to add warnings for suicidal behavior risks to a large class of epilepsy drugs also used widely for a variety of other conditions, "The Wall Street Journal" reported June 4.

On June 1, at a closed meeting of epilepsy researchers and industry representatives in New York, FDA presented data that agency officials said show a statistically significant difference in suicidal tendencies for patients who have taken one of 11 epilepsy drugs that are on the market. However, the difference is quite small; the risk of suicidal behavior for patients on a placebo was 0.23% and for those taking one of the 11 drugs it was 0.37%.

Related newspaper, magazine, and journal articles:

;

See all results. Or, try our Advanced Search.

We're searching over:

• 60 million articles
• 3,500 publications